These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 3136608)

  • 41. [Immunogenic properties of a polyvalent vaccine against Pseudomonas aeruginosa].
    Serafińska D; Bukowska D; Sokołowska K; Nasiłowski W
    Pol Tyg Lek; 1980 Jul; 35(27):1013-5. PubMed ID: 6775310
    [No Abstract]   [Full Text] [Related]  

  • 42. Pseudomonas aeruginosa ribosomal vaccine. A comparison of the immunogenicity of vaccines from two different serotypes.
    Lieberman MM
    Antibiot Chemother (1971); 1989; 42():193-202. PubMed ID: 2512837
    [No Abstract]   [Full Text] [Related]  

  • 43. Vaccines against Pseudomonas aeruginosa infection: 2. Clinico-immunological investigations.
    Krokhina MA; Grishina IA; Panova YuM ; Terekhova RP; Severtsova MK; Yedvabnaya LS; Vaide M; Varro R; Rusanov VM; Kolker II
    Vaccine; 1985 Sep; 3(3):316-24. PubMed ID: 3933202
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Alternative vaccination against equine botulism (BoNT/C).
    Frey J; Eberle S; Stahl C; Mazuet C; Popoff M; Schatzmann E; Gerber V; Dungu B; Straub R
    Equine Vet J; 2007 Nov; 39(6):516-20. PubMed ID: 18065309
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pseudomonas aeruginosa antigens as potential vaccines.
    Stanislavsky ES; Lam JS
    FEMS Microbiol Rev; 1997 Nov; 21(3):243-77. PubMed ID: 9451816
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Adjuvanted Lyme disease vaccine: a review of its use in the management of Lyme disease.
    Onrust SV; Goa KL
    Drugs; 2000 Feb; 59(2):281-99. PubMed ID: 10730551
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antibodies to lipopolysaccharides after immunization of humans with the rough mutant Escherichia coli J5.
    Baumgartner JD; Heumann D; Calandra T; Glauser MP
    J Infect Dis; 1991 Apr; 163(4):769-72. PubMed ID: 2010630
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of Tdap when administered before, with or after the 13-valent pneumococcal conjugate vaccine (coadministered with the quadrivalent meningococcal conjugate vaccine) in adults: A randomised controlled trial.
    Tashani M; Alfelali M; Barasheed O; Alqahtani AS; Heron L; Wong M; Rashid H; Booy R
    Vaccine; 2016 Nov; 34(48):5929-5937. PubMed ID: 27780630
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunological nonidentity of Pseudomonas paucimobilis with Pseudomonas aeruginosa and Pseudomonas cepacia.
    Smalley DL; Ourth DD
    J Clin Microbiol; 1980 Sep; 12(3):439-41. PubMed ID: 6783679
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pseudomonas aeruginosa infection and vaccination in the rat.
    Kostiala AA
    J Med Microbiol; 1980 May; 13(2):201-12. PubMed ID: 6770090
    [TBL] [Abstract][Full Text] [Related]  

  • 51. O-polysaccharide-protein conjugates induce high levels of specific antibodies to Pseudomonas aeruginosa immunotype 3 lipopolysaccharide.
    van de Wiel PA; Witvliet MH; Evenberg D; Derks HJ; Beuvery EC
    Vaccine; 1987 Mar; 5(1):33-8. PubMed ID: 2437718
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Conformation-dependent antibody response to Pseudomonas aeruginosa outer membrane proteins induced by immunization in humans.
    Lee N; Ahn B; Jung SB; Kim YG; Kim H; Park WJ
    FEMS Immunol Med Microbiol; 2000 Jan; 27(1):79-85. PubMed ID: 10617794
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety and immunogenicity of a Pseudomonas aeruginosa O-polysaccharide toxin A conjugate vaccine in humans.
    Cryz SJ; Fürer E; Cross AS; Wegmann A; Germanier R; Sadoff JC
    J Clin Invest; 1987 Jul; 80(1):51-6. PubMed ID: 3110215
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Human IgG subclass responses in relation to serum bactericidal and opsonic activities after immunization with three doses of the Norwegian serogroup B meningococcal outer membrane vesicle vaccine.
    Naess LM; Aarvak T; Aase A; Oftung F; Høiby EA; Sandin R; Michaelsen TE
    Vaccine; 1999 Feb; 17(7-8):754-64. PubMed ID: 10067680
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Defective IgG2 response to Pneumovax in HIV seropositive patients.
    Unsworth DJ; Rowen D; Carne C; Sonnex C; Baglin T; Brown DL
    Genitourin Med; 1993 Oct; 69(5):373-6. PubMed ID: 8244356
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antibody response to pneumococcal vaccine in splenectomized children.
    Pedersen FK
    Acta Pathol Microbiol Immunol Scand C; 1983 Apr; 91(2):169-80. PubMed ID: 6880749
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vaccination-induced circulation of human B cells secreting type-specific antibodies against pneumococcal polysaccharides.
    Heilmann C; Henrichsen J; Pedersen FK
    Scand J Immunol; 1987 Jan; 25(1):61-7. PubMed ID: 3492757
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Experimental immunisation of hamsters with lipopolysaccharide antigens of Leptospira interrogans.
    Jost BH; Adler B; Faine S
    J Med Microbiol; 1989 Jun; 29(2):115-20. PubMed ID: 2733021
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and immunogenicity testing of an intranasal group B meningococcal native outer membrane vesicle vaccine in healthy volunteers.
    Drabick JJ; Brandt BL; Moran EE; Saunders NB; Shoemaker DR; Zollinger WD
    Vaccine; 1999 Aug; 18(1-2):160-72. PubMed ID: 10501246
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Live Shigella flexneri 2a and Shigella sonnei I vaccine candidate strains with two attenuating markers. II. Preliminary results of vaccination of adult volunteers and children aged 2-17 years.
    Dentchev V; Marinova S; Vassilev T; Bratoyeva M; Linde K
    Vaccine; 1990 Feb; 8(1):30-4. PubMed ID: 2180231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.